The pursuit for biotherapeutic proteins in basic research, clinical diagnostics and therapy continues at an exponential pace. Consequently, the demands for efficient expression and production of these valuable biomolecules face challenges to improve quantity and quality while minimising time and cost. Thus, an increasing variety of recombinant production platforms, called “cell factories,” are being developed. Unfortunately, there is no universal production system which can guarantee high yields, since each protein can vary in terms of expression and production.
Humanization and Simultaneous Optimization of Monoclonal and Bispecific Antibody
Christine X. Koo, PhD, Senior Scientist I, Lead optimization, Chugai Pharmabody Research
Rapid Selection of CHO Clones Secreting Chimeric Antibody-Antigen Fusion Constructs Based on 2A-Peptide Cleavage and GFP
Bert Devriendt, PhD, Postdoctoral Scientist, Department of Virology, Parasitology, Immunology, Physiology, Ghent University
High Throughput Antibody Production and Purification: Day to Day Challenges and How to Overcome Them
Peter Schmidt, PhD, Director, Recombinant Technologies Research, CSL Behring
High Density (HD) Expression Platform: The One-Stop-Solution for Recombinant Antibody Production
Bowu Luan, PhD, Product Manager, GenScript USA, Inc.
The Use of Design of Experiments in Recombinant Protein Production; Concepts and Case Studies
Barry Ryan, BSc (Hons), PGDip, MSc, MA, PhD, Lecturer, Food Science and Environmental Health, College of Health and Science, Technological University Dublin
Tuning Recombinant Protein Expression to Match Secretion Capacity
Neil Dixon, PhD, David Phillips Research Fellow, Manchester Institute of Biotechnology, University of Manchester
A Recovery Toolbox: Molecular Approaches to Enhance Protein Folding and Soluble Yield from Bacterial Expression Systems
Christopher H. Gray, PhD, Team Leader (Structural Biology), Drug Discovery Program, CRUK Beatson Institute
Improved Production of Recombinant Proteins from Insect Cells through Promoter, Virus, and Strain Enhancements
Dominic Esposito, PhD, Director, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research
Production of Hard-to-Produce Proteins Using Genome Engineered CHO Cells
Bjørn Voldborg, MSc, Director, CHO Cell Line Development, The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark
High-Yield Production of "Difficult-to-Express" Proteins in an Improved Cell-Free System
Takanori Kigawa, DSci, Team Leader, Center for Biosystems Dynamics Research, RIKEN
TRANSIENT EXPRESSION SYSTEMS
Choosing Right between Transient and Stable Protein Expression Systems while Supporting Fast-Paced Biologics Discovery
Kinjal Mehta, PhD, Principal Scientist, Protein Sciences, Jounce Therapeutics
Scaling Up and Scaling Out: Pushing the Boundaries of Transient Protein Production
Ian Wilkinson, PhD, CSO, Absolute Antibody Ltd.
* The program is subject to change without notice, due to unforeseen reason.